Fecal microbiota transplantation for immune checkpoint inhibitors(FMT for ICI)

Feasible study on the effect of fecal microbiota transplantation on antitumor response with immune checkpoint inhibitors(FMT for ICI) - Fecal microbiota transplantation for immune checkpoint inhibitors(FMT for ICI)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041200003

Enrollment

Registered

2020-04-17

Start date

2020-04-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumors for which immune check point inhibitors are indications

Interventions

fecal microbiota transplatation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with the agreement in a document

Exclusion criteria

Exclusion criteria: 1.Difficulty in FMT 2.Allergy to drugs used 3.Judged as unsuitable by researchers

Design outcomes

Primary

Measure	Time frame
Difference in fecal microbiota between responsive and unresponsive groups by immune check point inhibitors	—

Secondary

Measure	Time frame
Response rate and disease control rate of immune check point hinhibitors after fecal microbiota transplantation PD-L1 expression, tumor-infiltrating T lympohocytes, and tumor mutational burden of tumors Surface markers of peripheral blood lymphocytes before and after fecal microbiota transplantation	—

Contacts

Public ContactNaoki Ohmiya

Fujita Health University Hospital

nohmiya@fujita-hu.ac.jp+81-562-93-9240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026